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Prostate cancer (PC) is the most common noncutaneous malignancy aﬀecting men in the US, leading to signiﬁcant morbidity and
mortality. While signiﬁcant therapeutic advances have been made, available systemic therapeutic options are lacking. Prostate-
speciﬁc membrane antigen (PSMA) is a highly-restricted prostate cell-surface antigen that may be targeted. While initial anti-
PSMA monoclonal antibodies were suboptimal, the development of monoclonal antibodies such as J591 which are highly speciﬁc
for the external domain of PSMA has allowed targeting of viable, intact prostate cancer cells. Radiolabeled J591 has demonstrated
accurate and selective tumor targeting, safety, and eﬃcacy. Ongoing studies using anti-PSMA radioimmunotherapy with 177Lu-
J591 seek to improve the therapeutic proﬁle, select optimal candidates with biomarkers, combine with chemotherapy, and prevent
or delay the onset of metastatic disease for men with biochemical relapse. Anti-PSMA monoclonal antibody-drug conjugates
have also been developed with completed and ongoing early-phase clinical trials. As PSMA is a selective antigen that is highly
overexpressed in prostate cancer, anti-PSMA-based immunotherapy has also been studied and utilized in clinical trials.
1. Prostate-SpeciﬁcMembrane Antigen
Prostate-speciﬁc membrane antigen (PSMA) is the single
most well-established, highly speciﬁc prostate epithelial cell
membrane antigen known [1–6]. The PSMA gene has
been cloned, sequenced, and mapped to chromosome 11p
[2, 7]. Pathology studies indicate that PSMA is expressed
by virtually all prostate cancers [7–10]. Moreover, PSMA
expression increases progressively in higher-grade cancers,
metastatic disease and castration-resistant prostate cancer
(CRPC) [3, 4, 11, 12]. Although ﬁrst thought to be entirely
prostate-speciﬁc [1–3], subsequent studies demonstrated
that cells of the small intestine, proximal renal tubules,
and salivary glands also express PSMA [5]. Importantly,
the expression in normal cells is 100–1000-fold less than in
prostate tissue [6], and the site of expression is not typically
exposed to circulating intact antibodies [5]. In addition,
PSMA is expressed on the neovasculature of the vast
majority of solid tumor malignancies, but not on the normal
vasculature [13]. In contrast to other well-known prostate-
restricted molecules such as prostate-speciﬁc antigen (PSA)
and prostatic acid phosphatase (PAP) that are secretory
proteins, PSMA is an integral cell-surface membrane protein
that is not secreted, thereby making PSMA an ideal target for
monoclonal antibody (mAb) therapy.
Prostate-speciﬁc membrane antigen has been found to
have folate hydrolase and neurocarboxypeptidase activity
[14]. Although its role in prostate cancer (PC) biology
is unknown, the consistent ﬁnding of PSMA upregulation
correlating with increased aggressiveness of the cancer
implies that PSMA has a functional role in PC progression.
Inhibition of enzymatic activity in vitro or in xenograft
models has not demonstrated signiﬁcant growth inhibitory
eﬀect (N. H. Bander et al., unpublished data). Nevertheless,
the expression pattern of PSMA makes it an excellent target
for mAb-based targeted therapy of PC.
Prostate-speciﬁc membrane antigen was initially vali-
dated as an in vivo target for imaging utilizing radiolabeled
mAb 7E11 (CYT-356, capromab) [15, 16]. Capromab pen-
detide imaging wasapprovedto evaluatetheextent ofdisease
in patients presenting with Gleason sums greater than 6
and those who experience a rising PSA after prostatectomy.2 Advances in Urology
Though improvements have been made with single-photon
emission computed tomography (SPECT) and SPECT/CT
imaging, because of suboptimal sensitivity and speciﬁcity
of capromab pendetide, this imaging tool has not been
widely adopted [17, 18]. Molecular mapping revealed that
7E11 targets a portion of the PSMA molecule that is
within the cell’s interior and not exposed on the outer cell
surface [5, 19, 20] and cannot bind to viable cells [1, 20].
Recognition of these features by Bander and colleagues at
Weill Cornell Medical College led to the development of
mAbs to the exposed, extracellular domain of PSMA. In
theory, the bound mAbs to the PSMA molecule would have
the potential to signiﬁcantly improve in vivo targeting and
likely result in enhanced imaging and therapeutic beneﬁt
[20–22]. After testing, these antibodies (J591, J415, J533, and
E99) did indeed demonstrate high-aﬃnity binding to viable
PSMA-expressing LNCaP cells in tissue culture and were
rapidly internalized [20, 21]. Amongst these antibodies, the
deimmunized IgG monoclonal antibody known as J591 was
the most highly developed antibody clinically [23].
2. Radioimmunotherapy: Background and
Rationale for Prostate Cancer
Radioimmunotherapy (RIT) is a technique by which a
radionuclide is linked to a mAb or peptide and is typically
deliveredinasystemicfashion.Inclinicalpractice,mAbsand
peptides can be labeled with radionuclides that are usually
beta-emitters. This “targeted” form of RT allows radiation
delivery to tumors while sparing normal organs. The initially
investigated form of RIT utilized radiolabeled antibodies
against carcinoembryonic antigen for solid tumors. To date,
the most studied form of RIT targets the CD20 antigen
(131I tositumomab or 90Y ibritumomab tiuxetan) in non-
Hodgkin’s lymphoma, demonstrating safety and eﬃcacy in
phase I–III trials, which led to FDA approval. RIT for solid-
tumor malignancies has been slower to develop. Reasons for
this are multifaceted, including lack of speciﬁc antigens and
antibodies optimized for RIT, diﬃculties in stably linking
radionuclides to existing mAbs, shortfalls in existing (and
readily available) radionuclides, and diﬃculty in clinical use
(coordination between diﬀerent specialties) [24]. However,
clinical trials utilizing RIT in solid-tumor malignancies have
been increasing.
The most common radionuclides employed have been
90Ya n d131I, with 177Lu being used more recently. Based
on the physical properties, each radionuclide may have an
optimaltumortypeandperformuniquefunctionsinclinical
situations [25]( Table 1).
Prostate cancer is an ideal solid tumor malignancy for
the utilization of RIT; the tumor is radiosensitive with high
exposure to circulating antibodies (bone marrow and lymph
nodes) through typical distribution. Although sometimes
clinically problematic, early readouts of eﬃcacy can be
examined using serum prostate-speciﬁc antigen (PSA) levels.
In preclinical and clinical PC settings, radionuclides have
been linked to antibodies and/or peptides against mucin,
ganglioside (L6), Lewis Y (Ley), adenocarcinoma-associated
antigens, and PSMA [26–36]. Of these, PSMA is the most
speciﬁc and has been extensively studied in clinical trials.
Radioimmunotherapy can be delivered in a single dose
or in multiple fractions. The degree of antitumor response
following the administration of radiolabeled mAbs depends
on several variables, speciﬁcally total (cumulative) radiation
dose to the tumor, dose-rate, and tumor radiosensitivity. As
with conventional external beam ionizing radiotherapy, dose
fractionation may result in the ability to deliver a higher
tumor dose with less toxicity. At the optimal dose-rate,
fractionated dose RIT may decrease the amount of radiation
to bone marrow while increasing the cumulative radiation
dose to the tumor [37–39]. Preclinical data have shown
that dose fractionation or multiple low-dose treatments can
decrease toxicity while increasing the eﬃcacy [40–42]. Early
clinical studies have supported the ability to increase the
cumulative maximum tolerated dose by dose fractionation
[43–45].
Studies have shown that external beam RT can be
combined with cytotoxic chemotherapy and, though toxicity
may be increased, eﬃcacy of concurrent chemoradiotherapy
may be superior to sequential use. This may be especially
true when utilizing chemotherapeutic agents with radiosen-
sitizingeﬀects.CombiningRITwithcytotoxicchemotherapy
has also been investigated [30, 31, 46]. These combinations
have the possibility of increasing the therapeutic yield of RIT,
particularly in the face of bulky, metastatic solid tumors.
With “targeted” therapy in general, patient selection can
be signiﬁcant. While our ability to preselect optimal PC
patients based upon expression of a target has been limited,
in other tumor types, reviewing targeted expression can
be helpful in selecting patients more likely to respond or
eliminating patients with a very low chance of response.
For example, although epidermal growth factor receptor
(EGFR) expression as measured by immunohistochemistry
is not helpful in selecting patients for anti-EFGR mAb
therapy in advanced colorectal carcinoma, excluding those
with mutated K-ras has become helpful in clinical practice
[47]. Speciﬁcally for PSMA expression, use of quantita-
tive imaging, such as anti-PSMA-based positron emission
tomography (PET) [48] ,m a yb em o r ee ﬀective in selecting
the best candidates (or ruling out poor candidates) for
a PSMA-targeted therapeutic. When performing studies
aimed to develop and examine predictive biomarkers, one
must remember that prospective validation is important, as
development of a “targeted” therapy may be thwarted by a
suboptimal biomarker [49].
3. Anti-Prostatic-SpeciﬁcMembrane
Antigen-Based Radioimmunotherapy
Based on its apparent clinical ability to target some sites
of disease, treatment studies were initiated utilizing radio-
labeled capromab (CYT-356). In a phase I dose-escalation
study, 12 patients with metastatic CRPC received 90Y-CYT-
356afterbiodistributionstudieswith 111In-CTY-356[26].As
expected with RIT, myelosuppression was the dose limiting
toxicity(DLT).Noobjectiveresponses(PSAorradiographic)Advances in Urology 3
Table 1: Radionuclide properties.
Radionuclide properties 131I 90Y 177Lu
Physical half-life(days) 8.05 2.67 6.7
Beta particles (mEv)
max 0.61 2.280 0.497
average 0.20 0.935 0.149
Range in tissue (mm)
max 2.4 12.0 2.20
average 0.4 2.7 0.25
Gamma emission (mEv) 0.364 None 0.113–0.208
Optimal size of tumor when
targeted for curability [25] 3–5 mm 28–42mm 1–3mm
Comments Cannot be used with internalizing
mAb’s
Lacks gamma emissions (cannot use for
imaging)
were noted. A subsequent phase II study utilizing 90Y-CYT-
356 was performed in men with biochemically recurrent
prostate cancer [30], yet the study was stopped after signiﬁ-
canttoxicity(myelosuppression)andlackofeﬃcacy(noPSA
decline) were seen in the ﬁrst 8patients.
After determining that capromab was not capable of
binding to viable PC cells, phase I clinical trials were
performed linking Yttrium-90 (90Y) or Lutetium-177 (177Lu)
to J591 via a DOTA chelate in patients with metastatic
CRPC [25, 37]. Each of these studies was designed to
deliver a single-dose of radiolabeled J591 intravenously
followed by planar gamma camera imaging ± SPECT (in
the case of 90Y-J591, imaging was performed after 111In-J591
administration). These trials deﬁned the DLT and maximum
tolerated dose (MTD) and further reﬁned dosimetry, phar-
macokinetics, and HAHA of the radiolabeled mAb conju-
gates and demonstrated preliminary evidence of antitumor
activity. The vast majority of patients demonstrated good
tumortargetingbyradiolabeledJ591.Arepresentativeplanar
gamma camera image of radiolabeled J591 is displayed in
Figure 1. As expected, based on the physical properties as
described above, the MTD of single-dose 177Lu-J591 was
higher (70mCi/m2) than that of 90Y-J591 (17.5mCi/m2)
[34, 35].
A phase II study was subsequently performed with 177Lu-
J591, conﬁrming safety, eﬃcacy, and tumor-targeting ability
[50]. In a dual-center study, men with progressive metastatic
CRPC received a 177Lu-J591 intravenously followed by
gamma camera imaging one week later. The results are
promising and majority of patients demonstrated accurate
targeting of known sites of metastatic disease, and PSA
declines. All subjects experienced reversible hematologic
toxicity without signiﬁcant hemorrhagic complications. No
serious drug-related nonhematologic toxicity occurred in
either cohort.
Inaggregate,basedonthephaseIandphaseIIdata,these
trials provide support that radiolabeled J591 is well tolerated
with reversible myelosuppression, accurately targets PC
metastatic sites, has antitumor activity, and is nonimmuno-
genic. However, as previously discussed, there are limitations
to RIT for solid tumors, and the physical properties of 177Lu
should be suboptimal in treating the population treated to
date (men with progressive metastatic CRPC were treated,
many of whom had bulky disease). Additional studies to
improve the therapeutic proﬁle are in progress.
Based upon the rationale above, a US Department of
Defense sponsored study utilizing fractionated dose 177Lu-
J591 has recently been completed with initial results of
the primary endpoint presented [51]. Men with progressive
metastatic CRPC received 2 fractionated doses two weeks
apart. Doses were escalated in cohorts of 3–6subjects,
with cohort 1 receiving 20mCi/m2 x2 and each successive
cohort undergoing dose escalation by 5mCi/m2 per dose
(10mCi/m2 cumulative dose increase per cohort). The
primary endpoint was to determine DLT and the cumulative
MTD of fractionated 177Lu-J591 RIT with pharmacokinetics
and dosimetry, and the secondary endpoint was eﬃcacy.
Dose limiting toxicity was deﬁned as severe thrombocytope-
nia (platelet count <15 or need for >3 platelet transfusions in
30 days), grade 4 neutropenia >7days, febrile neutropenia,
or grade >2 nonhematologic toxicity. Twenty-eight subjects
receivedtreatmentwithcumulativedosesofupto90mCi/m2
(highest planned dose). The median age was 72years with
median baseline PSA of 49ng/mL; the majority of subjects
had Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 1 and had bone metastases. The study
conﬁrmed the hypothesis that fractionated dosing would
allow higher cumulative doses of 177Lu-J591 be administered
with less toxicity.
Following progression on primary hormonal therapy,
chemotherapy can oﬀer symptomatic improvement as well
as incremental survival beneﬁt [52, 53]. However, responses
are transient and all men eventually suﬀer from progression
of disease as described above with single-agent anti-PSMA
based RIT. The combination of taxane chemotherapy with
RT has been used in several diseases because of the radiosen-
sitizing eﬀects of taxane-based chemotherapy [54–56]. In
addition to favorable results from fractionated RIT and the
radiosensitizing eﬀects of taxane-based chemotherapy, it is
hypothesized that the additional debulking by chemotherapy
will overcome some of the limits imposed by the physical
characteristics of 177Lu. Based upon this theory, a phase I4 Advances in Urology
(a) (b) (c) (d)
Figure 1: Radiolabeled J591 imaging. Left panels: Anterior (a) and posterior (b) images of pretreatment bony metastases on 99mTc-MDP
bone scan. Right panels: Anterior (c) and posterior (d) total body images obtained via dual-head gamma camera of sites of uptake 7days
after 177Lu-J591 administration. (note, antibody is partly cleared via the liver resulting in nonspeciﬁc 177Lu localization).
trial of docetaxel and prednisone with escalating doses of
fractionated 177Lu-J591 is ongoing [57].
As discussed above, the most studied form of RIT to
date targets the CD 20 antigen (131I tositumomab and
90Y ibritumomab tiuxetan) in non-Hodgkin’s lymphoma.
While approved in the relapsed setting, it appears that
these therapies have their greatest impact in the minimal
disease setting [58–63]. The vast majority of relapses after
local therapy for PC are initially “biochemical” only, that
is, with a rising PSA despite no evidence of cancer on
imaging, aﬀecting approximately 50,000 men per year in
the United States alone [64, 65]. Although there is no
proven overall survival beneﬁt in a prospective randomized
trial, radiotherapy as a salvage regimen can lead to long-
term survival in selected individuals [66–69]. Unfortunately,
most individuals subsequently suﬀer systemic progression
because of subclinical micrometastatic disease outside of the
radiation ﬁeld.
Based on the demonstrated ability of J591-based therapy
to successfully target known sites of disease and appar-
ent clinical eﬃcacy in the advanced setting, it is now
under investigation in the salvage setting (clinicaltrials.gov
NCT00859781). “Targeted radiotherapy” in the form of RIT
isanattractiveoptionwiththepossibilitybeingahigheryield
therapy in the minimal disease (biochemical only) setting.
T h ep r i m a r yo b j e c t i v eo ft h i st r i a li st op r e v e n to rd e l a y
radiographically evident metastatic disease. Radiolabeled
J591 imaging will also be explored as a possible way to detect
sitesofdiseaseinthosepatientswithbiochemicalrelapseand
no evidence of disease on standard scans (99mTc-MDP bone
scans and computed tomography or magnetic resonance
imaging) [70].
4. Anti-Prostatic-SpeciﬁcMembrane Antigen
Antibody-Drug Conjugates
Rather than linking a radionuclide to an mAb, a drug
or toxin can also be linked, forming an antibody-drug
conjugate (ADC) [71]. In this form of therapy, drugs may be
delivered to target cells, sparing normal cells from toxicity.
Many advances have been made in ADC technology. Gem-
tuzumab ozogamicin is an anti-CD33 mAb conjugated to
calicheamicinwhichwasapprovedbytheUSFDAin2000for
older patients with relapsed acute myeloid leukemia, though
it has recently been withdrawn from the market. Many
othersareinlate-stagedevelopment,includingtrastuzumab-
DM1(anti-Her2forbreastcancer),inotuzumab,ozogamicin
(anti-CD22 for non-Hodgkin’s lymphoma), and brentux-
imab vedotin (anti-CD30 for Hodgkin’s lymphoma).
MLN2704 is an ADC with maytansinoid 1 (DM1), which
is a potent microtubule-depolymerizing compound conju-
gatedtoJ591.PreclinicalactivitywithMLN2704wasdemon-
strated [72] leading to a phase I trial designed to explore
single ascending doses of the conjugate to deﬁne DLT, MTD,
and PK [73]. Twenty-three subjects with metastatic CRPC
received MLN2704 at doses ranging from 18–343mg/m2 in
an accelerated dose escalation scheme; 18 received at least
3doses.Grade≥3 toxicities occurred in 2subjects, including
1episodeofuncomplicatedfebrileneutropeniaandtransient
grade 3 elevation of transaminases. One subject (treated at
343mg/m2)a c h i e v e da>50% decline in PSA, and another
(treated at 264mg/m2) experienced a PR by RECIST along
with a >50% decline in PSA.
A subsequent multicenter phase I/II study was initiated
based on the above results [71]. Sixty-twosubjects receivedAdvances in Urology 5
multiple doses of MLN2704. Four regimens were tested,
w i t hP S Ad e c l i n e sm o s tf r e q u e n ta t3 3 0m g / m 2 every 2weeks
(2/6 had PSA decrease >50%, 2/6 had PSA stabilization).
Althoughresponsewasmodest,andtreatmentwaslimitedby
toxicity,utilizingaPSMAmAbmaybedeliveredintheclinic,
and work is in progress and work is in progress utilizing new
linkers to J591 designed to improve selective targeting.
Based on the PSMA selective expression in PC and the
principle above, additional researchers have initiated further
clinical work with toxin-conjugates that target PSMA. In the
preclinical setting, A5-PE40 and D7-PE40 are recombinant
anti-PSMA immunotoxins tested in vivo.H u a n ge ta l .
inhibited the tumor growth in mice bearing subcutaneous
LNCaP tumors with an immunotoxin consisting of the anti-
PSMA mAb E6 and deglycosylated ricin A [74]. Russell et
al. coupled the melittin-like peptide 101 to anti-PSMA mAb
J591 and obtained a signiﬁcant tumor growth inhibition in
mice [75]. Henry et al. used MLN2704 for the treatment of
CWR22 xenografts [76]. Els¨ asser-Beile et al. reviewed other
targeted systems against PSMA including RNA-aptamer-
based immunotoxins [77]. Preclinical activity has been
demonstrated in another mAb conjugated to monomethy-
lauristatin E (MMAE) that recognizes the external domain
of PSMA [78]. This work has led to a phase I dose-escalation
study that has shown to be tolerated at the initial dose
levels [79]. Additional early-stage clinical work has involved
utilizing enzymatic activation to release cytotoxic substances
in PSMA positive cells [80].
5. Anti-Prostatic-SpeciﬁcMembrane
Antigen Immunotherapy
Immunotherapy has been utilized in oncology over many
decades, but only relatively recently has an autologous cellu-
lar immunotherapy agent (sipuleucel-T) been approved for
clinical use in prostate cancer [81]. Though many attempts
at utilizing immunotherapy in PC have focused on PSA
[82, 83], as discussed, PSMA is an attractive target based on
its restricted sites of expression. Multiple vaccine approaches
have been utilized in preclinical models and have moved to
early-stage clinical trials [83–88].
In addition to the deimmunization process in the
transition from murine to human antibody, mAb J591 was
engineered to interact with human immune eﬀector cells
and trigger antibody-dependent cell-mediated cytotoxicity
(ADCC).Insomeoftheinitialstudieswith“cold”or“naked”
J591 (unconjugated J591 with or without small doses of
trace-labeled 111In-J591 for imaging purposes), stabilization
of previously rising PSA occurred [89, 90]. Evidence of a
dose-response relationship between mAb mass delivered and
induction of ADCC was observed in a dose-escalation study
enrolling patients with progressive CRPC [91]. One patient
who received 100mg of J591 had a >50% reduction in PSA.
Interleukin 2 (IL-2) promotes the proliferation and
enhances the secretory capacity of all major types of
lymphocytes, including T, B, and NK cells [92]. In addition,
through its eﬀects on NK cells, IL-2 stimulates antigen-
nonspeciﬁc host reactions that involve interplay between
NK cells and monocytes. Based on these functions, IL-2
may be useful as an immune stimulant, particularly in the
setting of cancer immunotherapy [93]. Within two weeks
of low-dose IL-2 treatment, selective expansion of human
CD3−, CD56+ NK cells was seen with a plateau after 4
to 6 weeks of therapy [94, 95]. Based on the hypothesis
that J591 plus IL-2 would work together to eﬀect a positive
immune response against prostate cancer, a combination
study was initiated [96]. Seventeen patients with recurrent
prostate cancer received continuous low-dose subcutaneous
IL-2 (1.2 × 106 IU/m2/day) daily for 8 weeks with weekly
intravenous infusions of J591 (25mg/m2) during weeks 4–
6. Therapy was well tolerated with a trend for those with
signiﬁcant NK cell expansion to be nonprogressors.
6. Conclusion
Insummary,PSMAisthemosthighlyspeciﬁcPCcell-surface
proteinknown.Prostatecancerrepresentsanidealdiseasefor
mAb-directed therapy, with PSMA as an optimal target. Cur-
rentstrategiesaimtoimproveuponpastsuccessesinutilizing
anti-PSMA mAbs to deliver toxic payloads speciﬁcally to PC
cells, minimizing damage to normal organs. Clinical use to
date include developments with anti-PSMA RIT and ADC.
Additionalworkinearlystagesofdevelopmentincludesanti-
PSMA vaccines and utilizing PSMA-targeted therapy with or
without other immune modulators to stimulate anti-PSMA
ADCC.
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